Back

Estrogen Receptor Enhancers Sensitive to Low Doses of Hormone Specify Distinct Molecular and Biological Outcomes

Kim, H. B.; Nandu, T.; Camacho, C. V.; Kraus, W. L.

2025-08-12 genomics
10.1101/2025.08.08.669412 bioRxiv
Show abstract

Adult women are typically exposed to estradiol (E2) concentrations of [~]100-200 pM, yet most cell-based studies use 100 nM. We determined the molecular effects of E2 concentrations spanning six orders of magnitude (1 pM to 100 nM) in breast cancer cells. Estrogen receptor alpha (ER) enhancers formed at low physiological doses of E2 (1-100 pM) are mechanistically distinct from those that form at high pharmacological doses (10-100 nM). They (1) form in open chromatin bound by FOXA1, (2) produce enhancer RNAs enriched with functional eRNA regulatory motifs (FERMs), and (3) drive expression of cell proliferation genes with promoter-proximal paused RNA polymerase II. Importantly, low dose ER enhancer usage is elevated in breast cancer patients with poor responses to aromatase inhibitors, likely as a continued response to low circulating levels of E2. Collectively, our results identify mechanistic differences between low and high dose ER enhancers that specify distinct biological outcomes.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.